36 Dead From Meningitis Outbreak : Will the Valid Compounding Act be able to avert such a tragedy from happening again? Insulin therapy for diabetes care management Seize the day : Provide patient care Push provider status for pharmacists A tragic lesson in risk management
FDA Approves Lebrikizumab-lbkz for Moderate-to-Severe Atopic Dermatitis
September 16th 2024Lebrikizumab-lbks is a targeted treatment that addresses the root cause of atopic dermatitis; by reducing inflammation throughout the body, it can help alleviate the dry, itchy, and irritated skin that often characterizes the condition.